$BGMS News

Cyclacel Pharmaceuticals Q1 EPS $(0.04) Up From $(11.52) YoY, Sales $778.000K

Bio Green Med Solution Q4 EPS $(2.21) Up From $(847.61) YoY, Sales $666.000K

Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update

Bio Green Med Solution Q3 EPS $(1.31) Up From $(2.70) YoY, Sales $81.000K Up From $10.000K YoY

Bio Green Med Solutio shares are trading higher after the company received a notice of allowance for a U.S. patent titled "CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE (WHICH EXHIBIT EXCELLENT ANTI-TUMOUR ACTIVITY)".

Bio Green Med Solutio shares are trading higher after the company received a notice of allowance for a U.S. patent titled "CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE (WHICH EXHIBIT EXCELLENT ANTI-TUMOUR ACTIVITY)".

Bio Green Med Solution, Formerly Cyclacel, Has Received A Notice Of Allowance For A U.S. Patent Titled "CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE (WHICH EXHIBIT EXCELLENT ANTI-TUMOUR ACTIVITY)".

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Cyclacel Pharmaceuticals announces 1-for-15 reverse stock split

Cyclacel Pharmaceuticals Announces Stock Split

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals Says David Lazar Buys $3.1 Million in Preferred Stock, Becomes Interim CEO

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar